Inappropriate schedule of product administration: FDA reporting patterns
174,471 FDA FAERS reports mention Inappropriate schedule of product administration. 69,347 reports have a serious outcome flag.
Medicines named as suspect
- Dupilumab: 18,503 reports
- Adapalene: 16,539 reports
- Infliximab: 13,760 reports
- Avobenzone: 12,550 reports
- Octocrylene: 12,549 reports
- Octisalate: 12,548 reports
- Insulin Glargine: 9,610 reports
- Secukinumab: 4,916 reports
- Vedolizumab: 3,920 reports
- Dulaglutide: 3,643 reports
- Valsartan: 3,210 reports
- Sacubitril: 2,884 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.